5 Best Day Trading Stocks To Buy

4. Tempest Therapeutics, Inc. (NASDAQ:TPST)

Number of Hedge Fund Holders: 6

Average Trading Volume as of November 2: 19.35 Million

Share Price Gain in Past Month: 1,093% 

Tempest Therapeutics, Inc. (NASDAQ:TPST) is a clinical-stage oncology company that develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. Lead product candidates of the firm are TPST-1495 and TPST-1120. Both are in Phase 1 trial for the treatment of solid tumors. The company is based in Brisbane, California. The stock has rallied in the past few weeks after the firm released positive data from the trials for TPST-1120. 

On October 11, HC Wainwright analyst Joseph Pantginis maintained a Buy rating on Tempest Therapeutics, Inc. (NASDAQ:TPST) stock and raised the price target to $47 from $35, noting that the data positions the firm strongly to add quite meaningful to the standard of care regiment in first-line hepatocellular carcinoma.

At the end of the second quarter of 2023, 6 hedge funds in the database of Insider Monkey held stakes worth $2,915,000 in Tempest Therapeutics, Inc. (NASDAQ:TPST), compared to 4 in the previous quarter worth $4,364,000.